Gossamer in Agreement with Merck for Solid Tumor Studies

Date : 11/12/2019 @ 12:56PM
Source : Dow Jones News
Stock : Gossamer Bio Inc (GOSS)
Quote : 25.89  1.23 (4.99%) @ 8:47PM

Gossamer in Agreement with Merck for Solid Tumor Studies

Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart

1 Month : From Nov 2019 to Dec 2019

Click Here for more Gossamer Bio Charts.

By Michael Dabaie


Gossamer Bio Inc. (GOSS) said it is in a clinical collaboration agreement with Merck & Co. Inc. (MRK) to evaluate the combination of Gossamer's investigational candidate GB1275 and Merck's Keytruda in patients with advanced solid tumors.

Gossamer will conduct a Phase 1/2 study, Keynote-A36, in advanced solid tumors, with the Phase 1 consisting of dose escalation of three GB1275 regimens including one with Keytruda. The Phase 2 consists of expansion cohorts evaluating GB1275 in combination with Keytruda or chemotherapy.

The KEYNOTE-A36 Phase 1/2 trial is underway, enrolling patients in the U.S. and U.K. to treat solid tumor types, including pancreatic, gastric, esophageal, colorectal, prostate and triple negative breast.

Gossamer said it expects to report initial data from the Phase 1 portion of the study in the second half of 2020.


Write to Michael Dabaie at michael.dabaie@wsj.com


(END) Dow Jones Newswires

November 12, 2019 07:41 ET (12:41 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest GOSS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.